San Francisco, CA, United States of America

Joel S Karliner

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: The United States Government as Represented by the Department of Veterans Affairs, University of California. Active years: 2015.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Joel S. Karliner

Introduction

Joel S. Karliner is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of cardiovascular diseases through his innovative research and patents. His work focuses on the use of interleukin-15 as a therapeutic agent for treating cardiovascular conditions.

Latest Patents

One of his key patents is titled "Use of interleukin-15 to treat cardiovascular diseases." This patent outlines methods and compositions for treating cardiovascular diseases by administering a cytokine either alone or in conjunction with other therapeutic agents. This innovative approach has the potential to improve treatment outcomes for patients suffering from cardiovascular issues. He holds 1 patent in this area.

Career Highlights

Throughout his career, Joel has worked with prestigious institutions, including the University of California and the United States Government as represented by the Department of Veterans Affairs. His experience in these organizations has allowed him to contribute significantly to medical research and innovation.

Collaborations

Joel has collaborated with esteemed colleagues such as Yerem Yeghiazarians and Andrew Boyle. These partnerships have further enhanced his research and development efforts in the field of cardiovascular health.

Conclusion

Joel S. Karliner is a pioneering inventor whose work in cardiovascular disease treatment showcases the importance of innovative research in medicine. His contributions continue to influence the field and offer hope for improved therapeutic options.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…